HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kuo, K.-T. Articles by Wang, L.-S. Search for Related Content PubMed PubMed Citation Articles by Kuo, K.-T. Articles by Wang, L.-S. Related Collections Esophagus - cancer

Ann Thorac Surg 2003;76:909-914
© 2003 The Society of Thoracic Surgeons

---

Original article: general thoracic

Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma

^a Division of Thoracic Surgery, Departments of Surgery and Pathology, Taipei-Veterans General Hospital, Taipei, Taiwan
^b National Yang-Ming University, Taipei, Taiwan

Accepted for publication April 22, 2003.

^* Address reprint requests to Dr Liang-Shun Wang, Division of Thoracic Surgery, Department of Surgery, Taipei-Veterans General Hospital, No. 201, 2nd Section, Shih-Pai Rd, Taipei 11217, Taiwan
e-mail: lswang{at}vghtpe.gov.tw

BACKGROUND: Esophageal cancer is one of the most aggressive malignancies in the world, and whether multiple therapeutic modalities could improve long-term survival remains controversial. Recent studies have shown an increase of cyclooxygenase-2 (COX-2) expression in various malignancies, but its clinicopathologic role in esophageal squamous cell carcinoma (ESCC) remains unclear.

METHODS: From 1993 to 1997, tissue samples from 96 patients with ESCC who underwent esophagectomy at our institution were collected for analysis. Cyclooxygenase-2 expression was examined by immunohistochemical staining, and further confirmed by Western blot analysis on six frozen tissues. Clinicopathologic data were analyzed to verify the significance.

RESULTS: Cyclooxygenase-2 immunoreactivity was detected in 59 of 96 ESCC specimens (61%), and COX-2 overexpression (COX-2 high) was observed in 49% (47 of 96) of ESCCs. Statistical differences between COX-2 high and COX-2 low were found with respect to the status of distant metastasis (M factor) (p = 0.035) and tumor stage (p = 0.04). The survival was not significantly different between patients with and without COX-2 overexpression (p = 0.43). Using the Cox regression analysis, only the N factor (p = 0.0034) and M factor (p = 0.0325) were independent prognostic factors.

CONCLUSIONS: Our results showed that in patients with ESCC, COX-2 overexpression was significantly correlated with fewer metastases and less advanced stage, but had no impact on survival. The status of local or distant lymph node metastasis was the most important prognostic factor. The biological role and pathophysiologic regulation of COX-2 overexpression in ESCC deserve further investigation.

This article has been cited by other articles:

				S. Sadeghi, C. J. Bain, N. Pandeya, P. M. Webb, A. C. Green, D. C. Whiteman, and for the Australian Cancer Study Aspirin, Nonsteroidal Anti-inflammatory Drugs, and the Risks of Cancers of the Esophagus Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1169 - 1178. [Abstract] [Full Text] [PDF]